title: [Systemic mastocytosis. A review of current diagnostic and therapeutic approaches].
abstract: Mastocytosis is a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells in skin, bone marrow, bone, gastrointestinal tract, liver, spleen and lymph nodes. Today, regarding its biological features, mastocytosis (with or without myeloid accompanying disorders) is considered to be a hematologic disease. The classification proposed by Metcalfe in 1991 is the most useful in caring for patients with mastocytosis. In this classification 4 groups are described: 1) indolent mastocytosis with or without extracutaneous involvement; 2) systemic mastocytosis with an associated hematologic disorder; 3) aggressive mastocytosis; 4) mast-cell leukemia. Cutaneous mastocytosis typically presents as urticaria pigmentosa or diffuse cutaneous mastocytosis and these patients usually have a benign course. On the contrary, systemic mastocytosis is a disease with an increased risk to develop an aggressive hematologic disorder. In these patients a second hematologic process, such as myeloproliferative or myelodysplastic syndrome or acute leukemia, may occur. These patients often present without skin involvement and they have a very poor prognosis. Mast cell is a medium-sized granulated cell releasing chemical mediators (histamine, heparin, protease and cytokines). Mast cells originate from pluripotent hemopoietic progenitor cells that express the CD34 antigen. Mast cells are present in the bone marrow and are distributed throughout the connective tissues. Recently a mast-cell growth factor (MGF) has been identified. Clinical symptoms occur from the release of chemical mediators and the pathologic infiltration of cells. Although no effective therapy for patients with Mastocytosis is known, some patients may benefit from corticosteroid and interferon alpha treatment. The present article gives an overview of current knowledge about the biology, heterogeneity and treatment of human mastocytosis.
authors.affiliation: Divisione di Oncologia ed Ematologia, Ospedale Carlo Poma, Mantova.
authors.forename: F
authors.initials: F
authors.lastname: Pari
authors.forename: M D
authors.initials: MD
authors.lastname: Zamagni
authors.forename: C
authors.initials: C
authors.lastname: Carnevali
authors.forename: M
authors.initials: M
authors.lastname: Pagani
authors.forename: C
authors.initials: C
authors.lastname: Rabbi
authors.forename: M
authors.initials: M
authors.lastname: Cantore
authors.forename: G
authors.initials: G
authors.lastname: Cavazzini
authors.forename: E
authors.initials: E
authors.lastname: Aitini
authors.forename: F
authors.initials: F
authors.lastname: Smerieri
mesh_terms: D006801:Humans; D008407:Mast Cells / Q000166:cytology / Q000502:physiology; D008415:Mastocytosis / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis